|
Bibliografia
1. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study.
Manger K; Kalden JR; Manger B
Br J Rheumatol. 1996;35: 669-75
2. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations.
Dayan M; Zinger H; Kalush F; Mor G; Amir-Zaltzman Y; Kohen F; Sthoeger Z; Mozes E
Immunology. 1997;90: 101-8
3.Long-term treatment of systemic lupus erythematosus with cyclosporin A.
Caccavo D; Lagana B; Mitterhofer AP; Ferri GM; Afeltra A; Amoroso A; Bonomo L
Arthritis Rheum. 1997; 40: 27-35
4. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Van Vollenhoven RF; McGuire JL
Ann Med Interne Paris. 1996;147: 290-6
5. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study.
Schroeder JO; Zeuner RA; Euler HH; Loffler H
J Rheumatol. 1996; 23: 71-5
6. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412.
Prinz JC; Meurer M; Reiter C; Rieber EP; Plewig G; Riethmuller G
J Am Acad Dermatol. 1996;34: 244-52
7. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?
Maeda K; Kimura R; Komuta K; Igarashi T
Scand J Rheumatol. 1997; 26: 24-9
8. Intravenous immunoglobulin therapy for refractory myositis Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
Intern Med. 1996; 35: 663-7
9. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
Kasteler JS; Callen JP
J Am Acad Dermatol. 1997; 36: 67-71
10. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
Lang B; Dooley J
J Pediatr. 1996; 128: 429-32
11. Gastrointestinal features of scleroderma.
Sjogren RW
Curr Opin Rheumatol. 1996; 8: 569-75
12. Advances in palliative care for the patient with scleroderma.
Herrick AL
Curr Opin Rheumatol. 1996; 8: 555-60
13. Scleroderma renal crisis.
Steen-VD
Rheum Dis Clin North Am. 1996; 22: 861-78
14. Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis.
Rudnicka L; Czuwara J; Barusinska A; Nowicka U; Makiela B; Jablonska S
Ann N Y Acad Sci. 1996; 803: 318-20
15. Scleroderma renal crisis is still a life-threatening syndrome.
Stratta P; Besso L; Ferrero S; Canavese C; Hollo S; Ottone S; Sandri L; Thea A; Mazzucco G
Ren Fail. 1996; 18: 567-74
16. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis.
Vlachoyiannopoulos PG; Tsifetaki N; Dimitriou I; Galaris D; Papiris SA; Moutsopoulos HM
Ann Rheum Dis. 1996; 55: 761-8
17. Development of ischemic colitis and scleroderma renal crisis following methylprednisolone pulse therapy for progressive systemic sclerosis.
Yamanishi Y; Yamana S; Ishioka S; Yamakido M
Intern Med. 1996; 35: 583-6
18. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Isaacs JD; Hazleman BL; Chakravarty K; Grant JW; Hale G; Waldmann H
J Rheumatol. 1996; 23: 1103-6
19. Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow-up and clinical outcome in 31 skin diseases
Owsianowski M; Garbe C; Ramaker J; Orfanos CE; Gollnick H
Hautarzt. 1996; 47: 114-23
20. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol. 1996; 23: 654-8
21. TI: Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy
Lancet. 1996; 347: 1453-8
22. Pilot study of antithymocyte globulin in systemic sclerosis.
Matteson EL; Shbeeb MI; McCarthy TG; Calamia KT; Mertz LE; Goronzy JJ
Arthritis Rheum. 1996; 39: 1132-7
|
|
|
